The global genomics market size was valued at USD 32.65 billion in 2023 and is projected to witness a compound annual growth rate (CAGR) of 16.5% from 2024 to 2030.
The growth of genomics market is attributed to factors such as growing demand for gene therapy, personalized medicine, drug discovery, increasing cancer incidence, and a significant increase in demand for consumer genomics in recent years. Moreover, increasing number of joint ventures and partnerships amongst market players is also expected to have a positive impact on the genomics market growth. For instance, in June 2022, Illumina, Inc., and Allegheny Health Network signed a collaboration for effective evaluation of the impact of in-house Comprehensive Genomic Profiling (CGP) to leverage patient care.
Gather more insights about the market drivers, restrains and growth of the Genomics Market
The COVID-19 pandemic outbreak had posed challenges to applications of genomics technology in terms of research and therapeutics. Nevertheless, some niche applications were of great use to mankind during the pandemic situation to facilitate immediate attention for designing effective diagnostics, effective therapeutics and steps to curb the spread of COVID-19. For example, the viral genome mutational rate (~1-2 bases per month) was gauged for validity of PCR cycle was estimated to understand the efficacy of the re-purposed anti-viral treatments and thereby the vaccine development process was streamlined.
Many genomic surveillance programs were launched country wise to understand the dynamics of pandemic situation and to effective preventive measures. For instance, in December 2020, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) was launched by the joint efforts of Department of Biotechnology (DBT), Ministry of Health, and ICMR with an aim to screen the genomic variations in the SARS-CoV-2 by sequencing technologies. Furthermore, country specific companies are providing consumer genomics services which is also expected to fuel the market size in coming years. One such company being Mapmygenome which is one of the pioneers in India offers DTC genomics services.
The increasing prevalence of inherited cancers is expected create a high demand for cancer genomics. The substantial understanding of human genome have targeted focus on use of various gene therapies for treatment of cancers by modern gene editing techniques such as CRISPR-Cas gene technology. For instance, in September 2022, a group of researchers at the University of California introduced the applications of precision genome editing agents for management of inherited retinal diseases (IRDs).
The development of high-throughput sequencing technologies such as Next-Generation Sequencing (NGS) and microarrays has generated massive amounts of genomic data. However, the rapid accumulation of this data from DNA sequencing and Electronic Health Records (EHRs) poses significant challenges and opportunities for the extraction of biologically or clinically relevant information. Phenome-wide association study (PheWAS) & genome-wide association study (GWAS) are helping researchers to study correlations between genotype and phenotype.
The market players are extensively working towards collaborations, expansions, acquisitions and huge capital investments to advance in research to understand rare diseases and to aid drug discovery. For instance, PacBio declares a collaboration with the Genomics England society for the utility of PacBio’s technology to detect genetic variation in unexplained rare disorders. The study is intended to re-sequence a selection of samples collected during Genomics England’s 100,000 genomes project to discover potential operational and clinical benefits of long-read sequencing for the identification of mutations associated with rare diseases.
Genomics Market Segmentation
Grand View Research has segmented the global genomics market based on application, technology, deliverables, end-use, and region:
Application & Technology Outlook (Revenue, USD Billion, 2018 - 2030)
• Functional Genomics
• Transfection
• Real-Time PCR
• RNA Interference
• Mutational Analysis
• SNP Analysis
• Microarray Analysis
• Epigenomics
• Bisulfite Sequencing
• Chromatin Immunoprecipitation (ChIP & ChIP-Seq)
• Methylated DNA Immunoprecipitation (MeDIP)
• High-Resolution Melt (HRM)
• Chromatin Accessibility Assays
• Microarray Analysis
• Pathway Analysis
• Bead-Based Analysis
• Microarray Analysis
• Real-time PCR
• Proteomics Tools (2-D PAGE; yeast 2-hybrid studies)
• Biomarker Discovery
• Mass Spectrometry
• Real-time PCR
• Microarray Analysis
• Statistical Analysis
• Bioinformatics
• DNA Sequencing
• Others
Technology Outlook (Revenue, USD Billion, 2018 - 2030)
• Sequencing
• PCR
• Flow Cytometry
• Microarrays
• Other technologies
Deliverables Outlook (Revenue, USD Billion, 2018 - 2030)
• Products
o Instruments/Systems/Software
o Consumables & Reagents
• Services
o NGS-based Services
o Core Genomics Services
o Biomarker Translation Services
o Computational Services
o Others
End-use Outlook (Revenue, USD Billion, 2018 - 2030)
• Clinical Research
• Academic & Government Institutes
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other End Users
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o China
o India
o Japan
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait
Browse through Grand View Research's Biotechnology Industry Research Reports.
• The global cell sorting market size was valued at USD 242.7 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2030.
• The global live cell imaging market size was valued at USD 2.48 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030.
Key Companies & Market Share Insights
The market players operating in the genomics market are adopting product approval to increase the reach of their products in the market and improve the availability of their products & services in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.
Key Genomics Companies:
• Agilent Technologies
• Bio-Rad Laboratories, Inc.
• BGI Genomics
• Color Genomics, Inc.
• Danaher Corporation
• Eppendorf AG
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Illumina, Inc.
• Myriad Genetics, Inc.
• Oxford Nanopore Technologies
• Pacific Biosciences of California, Inc.
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific, Inc.
• 23andMe, Inc.
Recent Development
• In November 2023, Fabric Genomics collaborated with DNAnexus and Oxford Nanopore Technologies for deployment of CLIA/CAP labs in pediatric and neonatal ICU’s. The labs will use Oxford Nanopore’s platforms to study genetic disorders in infants.
• In February 2023, Illumina, Inc. entered into a collaboration with African Centre of Excellence for Genomics of Infectious Diseases to start a training institute to increase genomic capabilities in African region
• In January 2023, SOPHiA GENETIC collaborated with the Memorial Sloan Kettering Cancer Center (MSK), a U.S. Cancer Center, to offer researchers and clinicians solutions to expand analytical and testing capabilities.
• In January 2023, Agilent Technologies, Inc. announced acquisition of Avida Biomed, a company that develops target enrichment workflows for clinical researchers utilizing NGS methods to study cancers.
• In April 2022, QIAGEN launched the Biomedical Knowledge Base in Europe, Japan, North America, and Australia to support data science applications in biotech companies
Order a free sample PDF of the Genomics Market Intelligence Study, published by Grand View Research.